Home The McGee Group The McGee Group Releases Eyewear Supporting Vera Bradley Foundation for Breast Cancer

The McGee Group Releases Eyewear Supporting Vera Bradley Foundation for Breast Cancer

Sunglasses incorporate new designs benefitting breast cancer research

The McGee Group, a family-owned, American eyewear company specializing in the design and manufacturing of eyewear, sunglasses, readers and cases, is pleased to announce the release of a collection of eyewear featuring the designs and patterns benefitting the Vera Bradley Foundation for Breast Cancer.

Each year, the Vera Bradley designs a series of unique patterns to help drive awareness and raise money for its Foundation’s ongoing work to support research for a cure for breast cancer. This year, The McGee Group has prepared three sunglass offerings that incorporate the two patterns developed for 2020, as well as 9 total SKUs that will be released from October through January with a portion of the proceeds going to support the foundation’s mission.

“One of the many reasons we consider Vera Bradley such a strong, trusted partner is because of our shared commitment in the pursuit of a cure for breast cancer,” said Matthew McGee, Executive Vice President at The McGee Group. “Each year, we’re honored to take the beautiful and unique patterns that are created for the foundation and incorporate them into a special collection to raise awareness, as well as funding, for this vitally important cause.”

Vera Bradley launched its efforts to raise money for breast cancer research in 1993, and it has secured nearly $35 million in contributions during the past 25 years. The foundation aims to raise funds to drive research and ultimately identify a cure to help those affected by the disease.

Researchers at the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine in Indianapolis, Indiana, collaborate and lead clinical trials with researchers nationwide. They are focused on developing and dramatically improving therapies for some of the most difficult-to-treat types of breast cancer, including triple negative breast cancer.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

- Advertisment -

Most Popular

Blink Boutique Eyecare + Eyewear: A Female Power Pair

Kimberly Pham, OD, and Alyssa Garza, OD, started out as full-time ODs working for the same owner. They had met in passing and each...

Revo Sunglasses Partners with Launchpad Vision for Direct Distribution in the Optical Channel

Revo is proud to announce a new direct sales structure for the optical channel through a unique partnership with Launchpad Vision, a commercialization services...

New Data Affecting Myopic Astigmatic Patients: NaturalVue Multifocal Demonstrates 100% Astigmatic Correction up to 2.00 D and 83% to 3.00 D

Visioneering Technologies, Inc. maker of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, unveiled significant findings at the Global Specialty Lens Symposium (GSLS). The...

Visioneering Announces Positive Interim 2-Year Data for their NaturalVue® Multifocal 1 Day Contact Lens from the PROTECT Multi-center, Randomized, Double-Masked Clinical Trial for Myopia...

Visioneering Technologies, Inc., manufacturer of NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, presented preliminary year 2 data from the ongoing 3-year PROTECT (PROgressive...